Microbiota-host genetic interactions modulate MASLD risk in PNPLA3 I148M carriers via ceramides and are reversible by targeted microbial interventions

Background The factors that determine when genetic susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) progresses to clinically significant liver injury remain incompletely understood. Objective We investigated whether disruption of the intestinal host-microbiota interface acts as a contextual modifier that amplifies PNPLA3 I148M -associated hepatic injury. Design We used a dual-hit mouse model combining hepatic Pnpla3 I148M -expression with Nlrp6 -deficiency, a model of impaired intestinal mucosal homeostasis, under western-diet conditions. Multi-omics profiling, including metagenomics, metabolomics and transcriptomics, was integrated with analyses in human cohorts (Lifelines, Charité MASLD, Human Phenotype Project). Microbiota-dependent effects were examined using faecal microbiota transplantation (FMT), antibiotic-mediated depletion and targeted intervention with Akkermansia muciniphila or its membrane protein Amuc_1100. Results In mice, the combination of Pnpla3 I148M expression and impaired intestinal sensing synergistically exacerbated gut-barrier dysfunction and bacterial encroachment, accompanied by increased portal levels of microbiota-associated metabolites, including long-chain ceramides (Cer(d18:1/16:0), Cer(d18:1/18:0)) and bile acids. These changes were associated with hepatic mitochondrial stress and inflammatory responses. Human carriers with advanced MASLD displayed microbial and metabolic signatures consistent with increased gut-derived metabolic signalling. Restoration of eubiotic microbiota via FMT or Amuc_1100 treatment improved intestinal barrier integrity and attenuated hepatic lipid accumulation in experimental models. Conclusion These findings suggest that gut-derived signals resulting from a disrupted intestinal barrier may act as modifiers of PNPLA3 I148M -clinical penetrance by amplifying downstream metabolic and inflammatory responses. By identifying these pathways linking environmental context to genetic susceptibility, this study highlights the host-microbiota interface as a potential target for strategies aimed at limiting MASLD progression in genetically at-risk individuals.

Authors

Institutions

Publication Details

Journal
Gut
Published
2026-10-05
DOI
https://doi.org/10.1136/gutjnl-2026-338178
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microbiota-host genetic interactions modulate MASLD risk in PNPLA3 I148M carriers via ceramides and are reversible by targeted microbial interventions

Marcus Henricsson, Till Robin Lesker, Anneleen Segers, Lena Susanna Candels et al.
Gut
Gut microbiota and health
article

Microbiota-host genetic interactions modulate MASLD risk in PNPLA3 I148M carriers via ceramides and are reversible by targeted microbial interventions

Marcus Henricsson, Till Robin Lesker, Anneleen Segers, Lena Susanna Candels, Ulrike Elisabeth Rolle-Kampczyk, Sonja Lang, Kai Markus Schneider, Carolin Victoria Schneider, Jan Georg Hengstler, Till Strowig, Willem M. de Vos, Münevver Demir, Martin von Bergen�, Frank Tacke, Mohamed Ramadan Mohamed, Yazhou Chen, Antonio Molinaro, Agata Anna Bielecka, Madhuri Haque, Christian Trautwein, Qusay Salih, Maria Backhaus, Thriveni Basavanapura, Lu Jiang
article en

Abstract

Background The factors that determine when genetic susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) progresses to clinically significant liver injury remain incompletely understood. Objective We investigated whether disruption of the intestinal host-microbiota interface acts as a contextual modifier that amplifies PNPLA3 I148M -associated hepatic injury. Design We used a dual-hit mouse model combining hepatic Pnpla3 I148M -expression with Nlrp6 -deficiency, a model of impaired intestinal mucosal homeostasis, under western-diet conditions. Multi-omics profiling, including metagenomics, metabolomics and transcriptomics, was integrated with analyses in human cohorts (Lifelines, Charité MASLD, Human Phenotype Project). Microbiota-dependent effects were examined using faecal microbiota transplantation (FMT), antibiotic-mediated depletion and targeted intervention with Akkermansia muciniphila or its membrane protein Amuc_1100. Results In mice, the combination of Pnpla3 I148M expression and impaired intestinal sensing synergistically exacerbated gut-barrier dysfunction and bacterial encroachment, accompanied by increased portal levels of microbiota-associated metabolites, including long-chain ceramides (Cer(d18:1/16:0), Cer(d18:1/18:0)) and bile acids. These changes were associated with hepatic mitochondrial stress and inflammatory responses. Human carriers with advanced MASLD displayed microbial and metabolic signatures consistent with increased gut-derived metabolic signalling. Restoration of eubiotic microbiota via FMT or Amuc_1100 treatment improved intestinal barrier integrity and attenuated hepatic lipid accumulation in experimental models. Conclusion These findings suggest that gut-derived signals resulting from a disrupted intestinal barrier may act as modifiers of PNPLA3 I148M -clinical penetrance by amplifying downstream metabolic and inflammatory responses. By identifying these pathways linking environmental context to genetic susceptibility, this study highlights the host-microbiota interface as a potential target for strategies aimed at limiting MASLD progression in genetically at-risk individuals.

Gut
University of Helsinki (FI), Helmholtz Centre for Environmental Research (DE), TU Dortmund University (DE), German Centre for Integrative Biodiversity Research (DE), Sahlgrenska University Hospital (SE), Medizinische Hochschule Hannover (DE), Universitätsklinikum Aachen (DE), Helmholtz Centre for Infection Research (DE), Centre for Individualised Infection Medicine (DE), University Hospital Cologne (DE), Klinikum Stuttgart (DE), University Hospital Carl Gustav Carus (DE), Leibniz Research Centre for Working Environment and Human Factors (DE), Center for Regenerative Therapies Dresden (DE), Technische Universität Dresden (DE), Charité - Universitätsmedizin Berlin (DE), University of Gothenburg (SE), RWTH Aachen University (DE), Wageningen University & Research (NL), Leipzig University (DE)
Openalex Percentile: Top 21%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.